 Genscript raised more than 1 billion from Hillhouse Capital in several different investments, including a 500 million commitment to Genscripts Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma formed a JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA vaccine in China. 